作者: Uta C. Hoppe , Jaime M. Casares , Hans Eiskjær , Arne Hagemann , John G.F. Cleland
DOI: 10.1161/CIRCULATIONAHA.106.614560
关键词: Incidence (epidemiology) 、 Randomized controlled trial 、 Atrial fibrillation 、 Heart failure 、 Cardiology 、 Internal medicine 、 Heart disease 、 Cardiac resynchronization therapy 、 Medicine 、 Hazard ratio 、 Adverse effect
摘要: Background— Atrial fibrillation/flutter (AF) and heart failure often coexist; however, the effect of cardiac resynchronization therapy (CRT) on incidence AF outcome patients with new-onset remains undefined. Methods Results— In CArdiac REsynchronisation in Heart Failure (CARE-HF) trial, 813 moderate or severe were randomly assigned to pharmacological alone addition CRT. The was assessed by adverse event reporting ECGs during follow-up, impact efficacy CRT evaluated. By end study (mean duration follow-up 29.4 months), had been documented 66 group compared 58 who received medical only (16.1% versus 14.4%; hazard ratio 1.05; 95% confidence interval, 0.73 1.50; P=0.79). There no difference time until first onset between groups. Mortality higher developed AF, but AF...